Quest Diagnostics Incorporated shows post-pandemic growth with Q3 results, strategic expansion, and steady returns. Click for ...

Medicare Part B data show that of the 20 CPT codes seeing the largest increase in payments from 2022 to 2024, all are for molecular- or sequencing-based tests.

Discover key insights into the global Revenue Cycle Management Market valued at USD 449.83 Billion in 2024, projected to skyrocket to USD 28,560 Billion by 2035, growing at a CAGR of 45.95%. Get ...

The firm hopes to exploit its first-mover advantage in the OTC space following de novo clearance for an at-home PCR test to detect sexually transmitted infections.

It is financial reporting season, and a few major medtech companies posted third-quarter sales growth. | It is financial ...

Shares of Quest Diagnostics (NASDAQ: DGX) are falling Tuesday after the medical laboratories company shared mixed earnings ...

Laboratory operator Quest Diagnostics raised its full-year forecast for profit and revenue on Tuesday, banking on robust demand for its diagnostic tests, after posting strong results for the third ...

While Quest Diagnostics raised its revenue and adjusted earnings guidance for full-year 2025, the company lowered its GAAP ...

Shares of Quest Diagnostics Inc. DGX slid 1.10% to $178.28 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.23% to ...

Strong growth, raised guidance, and new partnerships signal continued momentum amid regulatory and cost headwinds.

(DGX) on Tuesday reported third-quarter profit of $245 million.

Quest Diagnostics DGX is set to release its third-quarter 2025 results on Oct. 21, before the market opens. The renowned diagnostics provider posted adjusted earnings per share (EPS) of $2.62 in the ...